Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Researchers Characterize PrimPol, a Novel Human DNA Polymerase

By BiotechDaily International staff writers
Posted on 19 Nov 2013
PrimPol, a novel enzyme cloned in human cells, has been shown to initiate DNA chains with deoxynucleotides unlike regular primases, which exclusively use ribonucleotides.

Investigators at the biotechnology company SYGNIS AG (Madrid, Spain; and Heidelberg, Germany) in collaboration with researchers at the Spanish National Research Council (Madrid) recently isolated and characterized PrimPol.

They reported in the October 24, 2013, online edition of the journal Molecular Cell that PrimPol functioned as both DNA primase and DNA polymerase, and demonstrated high tolerance to damaged DNA. The primase function of PrimPol allowed it to begin reading and copying DNA without the need for random ribonucleotide primers, as required by all other commercially available polymerases. The use of random primers can bias sequencing and amplification results. The polymerase function of PrimPol displayed high specific activity, being extremely efficient when copying DNA strands with different lesions, such as abasic sites or 8-oxoguanine.

Subcellular fractionation and immunodetection studies showed that PrimPol could be found in both nuclear and mitochondrial DNA compartments. Its activity was detectable in mitochondrial lysates from human and mouse cells but was absent from mitochondria derived from mice that had been genetically engineered to lack the PRIMPOL gene. PRIMPOL gene silencing or ablation in human and mouse cells impaired mitochondrial DNA replication.

Senior author Dr. Luis Blanco, research professor at the Spanish National Research Council, said, "I am convinced that this fantastic enzyme will open numerous novel applications in the field of molecular biology, some of them we can only hint at this moment given the highly innovative potential of its key features."

SYGNIS AG is currently developing a new thermostable version of the enzyme that is expected to make an important contribution to the DNA amplification and sequencing field.

Related Links:

SYGNIS AG 
Spanish National Research Council



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.